{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T07:28:02Z","timestamp":1769758082944,"version":"3.49.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,9,25]],"date-time":"2015-09-25T00:00:00Z","timestamp":1443139200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s10096-015-2472-0","type":"journal-article","created":{"date-parts":[[2015,9,25]],"date-time":"2015-09-25T08:47:07Z","timestamp":1443170827000},"page":"2213-2223","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain"],"prefix":"10.1007","volume":"34","author":[{"given":"C.","family":"Rubio-Terr\u00e9s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Cobo Reinoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Grau Cerrato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Mensa Pueyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Salavert Llet\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Toledo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Anguita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Rubio-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Watt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Gani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,25]]},"reference":[{"key":"2472_CR1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","volume":"364","author":"TJ Louie","year":"2011","unstructured":"Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK; OPT- 80-003 Clinical Study Group (2011) Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364:422\u2013431","journal-title":"N Engl J Med"},{"key":"2472_CR2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","volume":"12","author":"OA Cornely","year":"2012","unstructured":"Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S; OPT-80-004 Clinical Study Group (2012) Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 12:281\u2013289","journal-title":"Lancet Infect Dis"},{"key":"2472_CR3","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2012.45.5899","volume":"31","author":"OA Cornely","year":"2013","unstructured":"Cornely OA, Miller MA, Fantin B, Mullane K, Kean Y, Gorbach S (2013) Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol 31:2493\u20132499","journal-title":"J Clin Oncol"},{"key":"2472_CR4","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/cid\/cir404","volume":"53","author":"KM Mullane","year":"2011","unstructured":"Mullane KM, Miller MA, Weiss K, Lentnek A, Golan Y, Sears PS, Shue YK, Louie TJ, Gorbach SL (2011) Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 53:440\u2013447","journal-title":"Clin Infect Dis"},{"key":"2472_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000351757","volume":"38","author":"KM Mullane","year":"2013","unstructured":"Mullane KM, Cornely OA, Crook DW, Golan Y, Louie TJ, Miller MA, Josephson MA, Gorbach SL (2013) Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials. Am J Nephrol 38:1\u201311","journal-title":"Am J Nephrol"},{"issue":"10","key":"2472_CR6","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.eimc.2012.11.007","volume":"31","author":"D Monge","year":"2013","unstructured":"Monge D, Mill\u00e1n I, Gonz\u00e1lez-Escalada A, Asensio A (2013) The effect of Clostridium difficile infection on length of hospital stay. A cohort study. Enferm Infecc Microbiol Clin 31(10):660\u2013664","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"2472_CR7","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3111\/13696998.2013.770749","volume":"16","author":"R Campbell","year":"2013","unstructured":"Campbell R, Dean B, Nathanson B, Haidar T, Strauss M, Thomas S (2013) Length of stay and hospital costs among high-risk patients with hospital-origin Clostridium difficile-associated diarrhea. J Med Econ 16:440\u2013448","journal-title":"J Med Econ"},{"key":"2472_CR8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.gastrohep.2008.02.003","volume":"32","author":"L Bujanda","year":"2009","unstructured":"Bujanda L, Cosme \u00c1 (2009) Diarrea asociada a Clostridium difficile. Gastroenterol Hepatol 32:48\u201356","journal-title":"Gastroenterol Hepatol"},{"key":"2472_CR9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.eimc.2011.09.010","volume":"30","author":"A Asensio","year":"2012","unstructured":"Asensio A, Monge D (2012) Epidemiolog\u00eda de la infecci\u00f3n por Clostridium difficile en Espa\u00f1a. Enferm Infecc Microbiol Clin 30:333\u2013337","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"2472_CR10","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S1473-3099(14)70991-0","volume":"14","author":"KA Davies","year":"2014","unstructured":"Davies KA, Longshaw CM, Davis GL, Bouza E, Barbut F, Barna Z, Delm\u00e9e M, Fitzpatrick F, Ivanova K, Kuijper E, Macovei IS, Mentula S, Mastrantonio P, von M\u00fcller L, Oleastro M, Petinaki E, Pituch H, Nor\u00e9n T, Nov\u00e1kov\u00e1 E, Ny\u010d O, Rupnik M, Schmid D, Wilcox MH (2014) Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infect Dis 14:1208\u20131219","journal-title":"Lancet Infect Dis"},{"key":"2472_CR11","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.medcli.2010.12.026","volume":"137","author":"D Monge","year":"2011","unstructured":"Monge D, Morosini M, Mill\u00e1n I, P\u00e9rez Canosa C, Manso M, Guzman MF, Asensio A (2011) Factores de riesgo de infecci\u00f3n por Clostridium difficile en pacientes hospitalizados. Med Clin (Barc) 137:575\u2013580","journal-title":"Med Clin (Barc)"},{"key":"2472_CR12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4321\/S1135-57272013000100004","volume":"87","author":"\u00c1 Asensio","year":"2013","unstructured":"Asensio \u00c1, Bouza E, Grau S, Rubio-Rodr\u00edguez D, Rubio-Terr\u00e9s C (2013) Coste de la diarrea asociada a Clostridium difficile en Espa\u00f1a. Rev Esp Salud Publica 87:25\u201333","journal-title":"Rev Esp Salud Publica"},{"key":"2472_CR13","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1093\/jac\/dks302","volume":"67","author":"AP Johnson","year":"2012","unstructured":"Johnson AP, Wilcox MH (2012) Fidaxomicin: a new option for the treatment of Clostridium difficile infection. J Antimicrob Chemother 67:2788\u20132792","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 6","key":"2472_CR14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/1469-0691.12046","volume":"18","author":"CP Kelly","year":"2012","unstructured":"Kelly CP (2012) Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect 18(Suppl 6):21\u201327. doi: 10.1111\/1469-0691.12046","journal-title":"Clin Microbiol Infect"},{"key":"2472_CR15","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2146\/ajhp110371","volume":"69","author":"T Crawford","year":"2012","unstructured":"Crawford T, Huesgen E, Danziger L (2012) Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection. Am J Health Syst Pharm 69:933\u2013943","journal-title":"Am J Health Syst Pharm"},{"key":"2472_CR16","unstructured":"Real Decreto-ley 16\/2012, de 20 de abril, de medidas urgentes para garantizar la sostenibilidad del Sistema Nacional de Salud y mejorar la calidad y seguridad de sus prestaciones. B.O.E. N\u00b0 98, 24 de abril de 2012: 31278."},{"key":"2472_CR17","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1093\/jac\/dku257","volume":"69","author":"D Nathwani","year":"2014","unstructured":"Nathwani D, Cornely OA, Van Engen AK, Odufowora-Sita O, Retsa P, Odeyemi IA (2014) Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. J Antimicrob Chemother 69:2901\u20132912","journal-title":"J Antimicrob Chemother"},{"key":"2472_CR18","unstructured":"fidaxomicin (Dificlir\u00ae) 200 mg film-coated tablet. All Wales Medicines Strategy Group, 1 June 2012"},{"key":"2472_CR19","unstructured":"Scottish Medicines Consortium. fidaxomicin 200mg film-coated tablets (Dificlir\u00ae). SMC No. (791\/12). Available online at: http:\/\/www.scottishmedicines.org.uk\/files\/advice\/fidaxomicin_Dificlir_FINAL_June_2012_for_website.pdf . Accessed 23 Sep 2014"},{"key":"2472_CR20","doi-asserted-by":"crossref","unstructured":"Lamotte M, Vellopoulou K, Richir K, Smets J, Grabe K, Coppens K (2013) The cost\u2013utility of fidaxomicin as compared to current standard treatment in the management of Clostridium difficile infections in Belgium. Value Health 16:A498","DOI":"10.1016\/j.jval.2013.08.1123"},{"key":"2472_CR21","doi-asserted-by":"crossref","first-page":"A353","DOI":"10.1016\/j.jval.2013.08.179","volume":"16","author":"A Engen Van","year":"2013","unstructured":"Van Engen A, Casamayor M, Loftus F, Crimin E, Lacey L (2013) Economic evaluation of fidaxomicin for the treatment of Clostridium difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in Ireland. Value Health 16:A353","journal-title":"Value Health"},{"issue":"Suppl 2","key":"2472_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1469-0691.12418","volume":"20","author":"SB Debast","year":"2014","unstructured":"Debast SB, Bauer MP, Kuijper EJ; European Society of Clinical Microbiology and Infectious Diseases (2014) European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 20(Suppl 2):1\u201326","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"2472_CR23","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s10198-013-0498-8","volume":"14","author":"C Eckmann","year":"2013","unstructured":"Eckmann C, Wasserman M, Latif F, Roberts G, Beriot-Mathiot A (2013) Increased hospital length of stay attributable to Clostridium difficile infection in patients with four co-morbidities: an analysis of hospital episode statistics in four European countries. Eur J Health Econ 14(5):835\u2013846","journal-title":"Eur J Health Econ"},{"key":"2472_CR24","doi-asserted-by":"crossref","unstructured":"Hart WM, Asensio A, Isidoro B, Watt M, Nazir J (2013) The burden of Clostridium difficile in Spain: a retrospective matched-cohort study. PIN 50. ISPOR 16th Annual European Congress. Dublin, pp 2\u20136","DOI":"10.1016\/j.jval.2013.08.160"},{"key":"2472_CR25","unstructured":"Hospital Episode Statistics (HES). Health & Social Care Information Centre (HSCIC). Available online at: http:\/\/www.hscic.gov.uk\/hes . Accessed 19 Nov 2013"},{"key":"2472_CR26","unstructured":"Consejo General de Colegios de Farmac\u00e9uticos. BOT Plus 2.0. Available online at: https:\/\/botplusweb.portalfarma.com\/ . Accessed 16 Oct 2013"},{"key":"2472_CR27","unstructured":"Ambulatory Diagnosis-Related Groups of the NHS. General Directorate of Public Health, Quality and Innovation. Specialized outpatient care in the National Health System. Weights and costs of outpatient procedures. IR-GRD 2.3. Ministry of Health, Social Services and Equality, Madrid. September 2013"},{"key":"2472_CR28","unstructured":"Pubic prices of Extremadura. Order of 7 February, 2014, publishing the updated list of public rates and prices of the Autonomous Community of Extremadura by virtue of the provisions of the General Budgets Law of the Autonomous Community of Extremadura for 2014. DOE no. 34, of 19 February, 2014"},{"key":"2472_CR29","unstructured":"Public prices of Madrid. Order 731\/2013 of 6 September, of the Ministry of Health, setting the public prices for the rendering of health services and activities of the Network of Centres of the Community of Madrid. DOE no. 215, of 30 September, 2013"},{"key":"2472_CR30","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3109\/17453671003587119","volume":"81","author":"GP Slobogean","year":"2010","unstructured":"Slobogean GP, O\u2019Brien PJ, Brauer CA (2010) Single-dose versus multiple-dose antibiotic prophylaxis for the surgical treatment of closed fractures. Acta Orthop 81:256\u2013262","journal-title":"Acta Orthop"},{"key":"2472_CR31","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3201\/eid1503.080312","volume":"15","author":"TJ Henrich","year":"2009","unstructured":"Henrich TJ, Krakower D, Bitton A, Yokoe DS (2009) Clinical risk factors for severe Clostridium difficile-associated disease. Emerg Infect Dis 15:415\u2013422","journal-title":"Emerg Infect Dis"},{"key":"2472_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jinf.2010.03.025","volume":"61","author":"JA Karas","year":"2010","unstructured":"Karas JA, Enoch DA, Aliyu SH (2010) A review of mortality due to Clostridium difficile infection. J Infect 61:1\u20138","journal-title":"J Infect"},{"key":"2472_CR33","unstructured":"Perras C, Tsakonas E, Ndegwa S, Conly J, Valiquette L, Farrah K (2011) Vancomycin or metronidazole for treatment of Clostridium difficile infection: clinical and economic analyses. Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa (technology report; no. 136). Available online at: http:\/\/www.cadth.ca\/media\/pdf\/H0499_Cdifficile_tr_e.pdf . Accessed 4 Dec 2013"},{"key":"2472_CR34","unstructured":"The human mortality database. Available online at: http:\/\/www.mortality.org\/hmd\/ESP\/STATS\/bltper_1x1.txt . Accessed 17 Oct 2013"},{"key":"2472_CR35","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/519265","volume":"45","author":"FA Zar","year":"2007","unstructured":"Zar FA, Bakkanagari SR, Moorthi KM, Davis MB (2007) A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45:302\u2013307","journal-title":"Clin Infect Dis"},{"key":"2472_CR36","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s10198-003-0182-5","volume":"4","author":"W Greiner","year":"2003","unstructured":"Greiner W, Weiinen T, Nieuwenhuizen M, Oppe S, Badia X, Busschbach J, Buxton M, Dolan P, Kind P, Krabbe P, Ohinmaa A, Parkin D, Roset M, Sintonen H, Tsuchiya A, de Charro F (2003) A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ 4:222\u2013231","journal-title":"Eur J Health Econ"},{"key":"2472_CR37","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0213-9111(02)71933-X","volume":"16","author":"JA Sacrist\u00e1n","year":"2002","unstructured":"Sacrist\u00e1n JA, Oliva J, Del Llano J, Prieto L, Pinto JL (2002) \u00bfQu\u00e9 es una tecnolog\u00eda eficiente en Espa\u00f1a? Gac Sanit 16:334\u2013343","journal-title":"Gac Sanit"},{"key":"2472_CR38","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Claxton K, Sculpher M (2006) Decision modelling for health economic evaluation. Oxford University Press, Oxford"},{"key":"2472_CR39","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0025-7753(04)74346-8","volume":"122","author":"C Rubio-Terr\u00e9s","year":"2004","unstructured":"Rubio-Terr\u00e9s C, Cobo E, Sacrist\u00e1n JA, Prieto L, del Llano J, Badia X; Grupo ECOMED (2004) An\u00e1lisis de la incertidumbre en las evaluaciones econ\u00f3micas de intervenciones sanitarias. Med Clin (Barc) 122:668\u2013674","journal-title":"Med Clin (Barc)"},{"key":"2472_CR40","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1086\/592981","volume":"30","author":"ER Dubberke","year":"2009","unstructured":"Dubberke ER, Wertheimer AI (2009) Review of current literature on the economic burden of Clostridium difficile infection. Infect Control Hosp Epidemiol 30:57\u201366","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"Suppl 6","key":"2472_CR41","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1469-0691.2006.01580.x","volume":"12","author":"EJ Kuijper","year":"2006","unstructured":"Kuijper EJ, Coignard B, T\u00fcll P; ESCMID Study Group for Clostridium difficile; EU Member States; European Centre for Disease Prevention and Control (2006) Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 12(Suppl 6):2\u201318","journal-title":"Clin Microbiol Infect"},{"key":"2472_CR42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jhin.2012.02.004","volume":"81","author":"PN Wiegand","year":"2012","unstructured":"Wiegand PN, Nathwani D, Wilcox MH, Stephens J, Shelbaya A, Haider S (2012) Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect 81:1\u201314","journal-title":"J Hosp Infect"},{"key":"2472_CR43","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/cid\/ciu128","volume":"58","author":"GG Konijeti","year":"2014","unstructured":"Konijeti GG, Sauk J, Shrime MG, Gupta M, Ananthakrishnan AN (2014) Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin Infect Dis 58:1507\u20131514","journal-title":"Clin Infect Dis"},{"key":"2472_CR44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4081\/idr.2013.e13","volume":"5","author":"S Bella Di","year":"2013","unstructured":"Di Bella S, Drapeau C, Garc\u00eda-Almod\u00f3var E, Petrosillo N (2013) Fecal microbiota transplantation: the state of the art. Infect Dis Rep 5:43\u201345","journal-title":"Infect Dis Rep"},{"key":"2472_CR45","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijantimicag.2013.10.009","volume":"43","author":"VL McCune","year":"2014","unstructured":"McCune VL, Struthers JK, Hawkey PM (2014) Faecal transplantation for the treatment of Clostridium difficile infection: a review. Int J Antimicrob Agents 43:201\u2013206","journal-title":"Int J Antimicrob Agents"},{"key":"2472_CR46","doi-asserted-by":"crossref","unstructured":"Bartsch SM, Umscheid CA, Fishman N, Lee BY (2013) Is fidaxomicin worth the cost? An economic analysis. Clin Infect Dis 57:555\u2013561","DOI":"10.1093\/cid\/cit346"},{"key":"2472_CR47","first-page":"302","volume":"5","author":"C Rubio Terr\u00e9s","year":"2006","unstructured":"Rubio Terr\u00e9s C (2006) M\u00e9todos para la realizaci\u00f3n de evaluaciones econ\u00f3micas de intervenciones sanitarias. GH Contin 5:302\u2013306","journal-title":"GH Contin"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-015-2472-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-015-2472-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-015-2472-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T10:38:16Z","timestamp":1718102296000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-015-2472-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,25]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["2472"],"URL":"https:\/\/doi.org\/10.1007\/s10096-015-2472-0","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,25]]}}}